Cisplatin is one of the most widely prescribed drugs for the treatment of solid tumors, even though its pharmacological potential is often limited by side effects (nephrotoxicity, neurotoxicity, alopecia) and a limited spectrum of activity. Overcoming these limitations is one of the most chased goals by researchers in the field of medicinal chemistry. Since phosphonates have a great selectivity for bone tissues, we have extended a previous study on a platinum(II) complex with a diethyl [(methylsulfinyl)methyl]phosphonate (smp) ligand, [PtCl 2 (S,O-smp)], to another phosphonate ester ligand, diethyl aminomethylphosphonate (amp). Further interest in this investigation was generated by the observation that [PtCl 2 (S,O-smp)] was capable of inhibiting matrix metalloproteinases (MMPs), which also play a role in tumor growth. The interaction of the amp ligand with the tetrachloroplati-